EXACT Therapeutics AS announces appointment of Anders Wold as Chair of the Board
OSLO/LONDON, 8 June 2022: EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical stage biopharmaceutical company with a mission to enhance the therapeutic efficacy of medicines through ultrasound-mediated drug delivery, today announces that Anders Wold, Board Director since December 2021, has been appointed Chair of the Board, with immediate effect.
Anders Wold started his career in the field of medical ultrasound in 1984 as he joined the start-up Vingmed which was acquired in 1998 by GE Healthcare. He has nearly forty years of leadership experience in the healthcare and ultrasound industry including President and CEO of GE Healthcare Clinical Care Solutions.
The current Executive Chair of the Board, Dr Masha Strømme will assume the role of Vice-Chair of the Board. Sir William Castell, current Vice-Chair of the Board, will assume the role of Director of the Board alongside Dr Jean-Michel Cosséry and Ann-Tove Kongsnes. Dr Aitana Peire did not seek re-election and on behalf of the shareholders, the Board of Directors would like to thank her for her support and excellent contribution.
Dr Masha Strømme, Executive Chair of the Board, commented: “We are delighted that Anders has accepted the role of Chair of the Board. He brings considerable experience in global markets and the Company will benefit tremendously from his leadership as we look to expand the clinical trials and development of the ACT® technology platform in the years ahead.”
Anders Wold, Director of the Board, stated: “These are exciting times for EXACT-Tx. ACT® is a unique technology in the crossover between Bio Pharma and Med Tech. I feel very privileged to take on this role at such an exciting time in the Company’s journey towards becoming a leading precision health company.”
ENDS
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email: per.walday@exact-tx.com
Dominic Moreland, CFO
EXACT Therapeutics
Email: Dominic@exact-tx.com
About EXACT-Tx
EXACT-Tx is a Norwegian clinical-stage precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101) activated by ultrasound for enhanced drug targeting deployed in multiple indications to enhance the therapeutic efficacy of medicines through the use of ultrasound-mediated drug delivery, for patients across multiple diseases. www.exact-tx.com
Forward looking statements
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.